Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

5.980 +0.440 (+7.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 408,929
Open 5.500
Bid (Size) 5.950 (2)
Ask (Size) 6.060 (33)
Prev. Close 5.540
Today's Range 5.486 - 6.150
52wk Range 5.010 - 11.18
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Compass Pathways appoints Teri Loxam as Chief Financial Officer
From Compass Pathways
Via GlobeNewswire
Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds
A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provi 
Via Benzinga

Performance

YTD
-22.54%
-22.54%
1 Month
-3.39%
-3.39%
3 Month
-36.52%
-36.52%
6 Month
-25.71%
-25.71%
1 Year
-42.11%
-42.11%

More News

Read More
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
From Compass Pathways
Via GlobeNewswire
Investing in Mental Health: 3 Stocks in the Wellness Space
Via InvestorPlace
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Via Benzinga
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex
Via Talk Markets
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
GH Research Drags Down Psychedelic Drug Stocks Index By 7%
Via Talk Markets
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Via Benzinga
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
Via Benzinga
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart
Via Talk Markets
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
Via Benzinga
Topics Economy
Exposures Interest Rates
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22%
Via Talk Markets
Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program
Via Benzinga
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
COMPASS Pathways announces CFO transition
From COMPASS Pathways
Via GlobeNewswire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Via Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Via Benzinga
Exposures Product Safety
Psychedelic-Compound-Based Drug Stocks Continue To Fall
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.